Evidence from CAR-T-induced CRS suggests parallels to the COVID-19 inflammatory response that would suggest that targeting IL-1β would reduce the inflammatory signaling that mediates lung injury, ARDS, and mortality. The gene discussed is IL1B; the disease is COVID-19.